AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 16, 2021
29864_dirs_2021-02-16_38628b4d-1d54-44e1-806c-d824d1b41c61.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-11
Reporting Person: ALTSHULER DAVID (EVP, Global Research and CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-11 | Common Stock | S | 4783 | $210.42 | Disposed | 53598 | Direct |
| 2021-02-11 | Common Stock | S | 500 | $211.67 | Disposed | 53098 | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.42 (range $209.91 to $210.89).
F3: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.67 (range $211.25 to $212.21).